Ademetionine 400 mg Tablet is a uniquely versatile product. Salvus Pharma is launching an exclusive PCD Pharma franchise for our brand, Adysil 400, in Bhopal, offering a strategic dual-market business.
- The Problem: A Dual Healthcare Challenge The Bhopal market faces two significant, growing health concerns:
- A rise in lifestyle-related liver health issues (fatty liver).
- An aging population seeking relief from the chronic pain of osteoarthritis. Pharma professionals need a product that can serve these high-potential markets.
- The Solution: A Dual-Action Therapeutic Agent Adysil 400 (Ademetionine) is the perfect solution. It is a single product trusted by two different specialties. As a hepato-protectant, it is prescribed by gastroenterologists for liver support. As a chondroprotective agent, it is used by orthopedicians to manage osteoarthritis.
- The Opportunity: Two Businesses in One This is your chance to build a resilient business by dominating two specialist segments. We offer the Ademetionine 400 mg PCD franchise in Bhopal on a monopoly basis. You get to capture both the gastro and ortho markets with one WHO-GMP certified, high-demand product.
Capture the Dual-Market in Bhopal: To learn more about this unique Adysil 400 franchise opportunity, contact Salvus Pharma. Contact Us: Call +91 9888902349 or email marketing@salvuspharma.in.
